Deepan Selvadurai, MD
Ophthalmology · Orchard Park, NYNPI 1790795433
Payments from drug & device makers
Across 391 payments — averaging $198.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sight Sciences, Inc.$72K
- Alcon$1K
- AbbVie$1K
- Aerie Pharmaceuticals, Inc.$404
- Novartis$306
- Bausch & Lomb Americas Inc.$296
- plus $2K from 21 others
Across 7 payments — averaging $2635.71 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sight Sciences, Inc.$18K
What the payments were for
- Consulting fees$27,70136%
- Speaking & faculty fees$38,96750%
- Travel & lodging$1,8602%
- Food & beverage$8,85311%
- Education$180%
- Other$510%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sight Sciences, Inc. | 101 | $71,683 |
| Alcon | 77 | $1,485 |
| AbbVie(2 entities) | 57 | $1,213 |
| Aerie Pharmaceuticals, Inc. | 38 | $404 |
| Novartis | 20 | $306 |
| Bausch & Lomb Americas Inc. | 15 | $296 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 14 | $293 |
| Sun Pharmaceutical Industries Inc. | 13 | $283 |
| NEW World Medical,inc. | 15 | $247 |
| Glaukos Corporation | 2 | $218 |
| Kala Pharmaceuticals, Inc. | 5 | $196 |
| Ivantis, Inc | 3 | $140 |
| Oyster Point Pharma, Inc. | 5 | $111 |
| Amgen(2 entities) | 6 | $90 |
| Thea Pharma Inc. | 3 | $67 |
| Tarsus Pharmaceuticals, Inc. | 2 | $65 |
| Carl Zeiss Meditec USA, Inc. | 1 | $51 |
| Rayner Intraocular Lenses Limited | 2 | $49 |
| Biotissue Holdings Inc. | 2 | $43 |
| Johnson & Johnson Surgical Vision, Inc. | 2 | $43 |
| Apellis Pharmaceuticals, Inc. | 2 | $39 |
| ANI Pharmaceuticals, Inc. | 1 | $25 |
| Alimera Sciences, Inc. | 1 | $23 |
| Rxsight Inc | 1 | $22 |
| Shire North American Group Inc | 1 | $22 |
| Dompe US, Inc. | 1 | $17 |
| Spark Therapeutics, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OMNI$37,384
- OMNI(R) SURGICAL SYSTEM (US)$32,749
- SION SURGICAL INSTRUMENT$10,886
- iDoseTR$201
- INVELTYS$116
How this compares
$77,450 in reported general payments places this provider in the 90th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RhopressaNetarsudil Mesylate | 275 | $128,835 |
| RocklatanNetarsudil Mesylat/Latanoprost | 193 | $98,278 |
| Brimonidine Tartrate | 623 | $61,210 |
| LumiganBimatoprost | 111 | $60,748 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 167 | $51,368 |
| Prednisolone Acetate | 1,205 | $40,480 |
| Cyclosporine | 58 | $34,447 |
| Brinzolamide | 122 | $33,431 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 1,087 | $32,607 |
| VyzultaLatanoprostene Bunod | 48 | $30,207 |
| RestasisCyclosporine | 26 | $28,074 |
| Latanoprost | 1,409 | $26,775 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 76 | $24,221 |
| CombiganBrimonidine Tartrate/Timolol | 56 | $21,981 |
| Timolol Maleate | 659 | $21,244 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan | $404 | $227,113468 claims |
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,213 | $119,191222 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $296 | $30,20748 claims |
| AlconSimbrinza | $1,485 | $24,22176 claims |
| Thea Pharma Inc.Iyuzeh | $67 | $7,01018 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate | $293 | $2,36012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in Orchard Park
- Douglas JabsNew York$24.3M
- David RubaltelliBrooklyn$8.9M
- Philip FerroneGreat Neck$5.8M
- Eric DonnenfeldGarden City$2.6M
- Nathan RadcliffeNew York$2.4M
- Glenn StollerRockville Centre$2.1M
- Richard SpaideNew York$1.7M
- Paul HartmanRochester$1.6M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.